Schwabe Kaloba Pelargonium Cough and Cold Relief Tablets, 30 g

Product Information

Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial. Explore (NY). 2005;1(6):437-445. The committee agreed that because the evidence of benefit of doxycycline over amoxicillin, clarithromycin or erythromycin is limited, these antibiotics should be offered as alternative first choices. This also reflects concerns that doxycycline is contraindicated in pregnancy, and this should be considered when choosing antibiotics for women of childbearing age. Not required as per article 16 c (1) (a) (iii) of Directive 2001/83/EC as amended. 5.3 Preclinical safety data P. sidoides tablets (any dosage) significantly reduced 'failure to resolve all symptoms' by day 7 (92.7% versus 99.0%; low quality evidence) and 'failure to resolve cough' by day 7 (low quality evidence) compared with placebo in adults with acute bronchitis, although, individually, only the 30‑mg dose achieved a significant reduction for 'failure to resolve cough' (low quality evidence).

Scientists claim that Pelargonium Sidoides can help fight upper respiratory tract infections like bronchitis, sinusitis, and the common cold. That is because it naturally increases the body’s healing ability. For example, individuals with acute bronchitis ultimately can resolve the symptoms within a week of its consumption. Macrolides should be used with caution in people with a predisposition to QT interval prolongation. Nausea, vomiting, abdominal discomfort, and diarrhoea are the most common side effects of macrolides. These are less frequent with clarithromycin than with erythromycin ( BNF, December 2018). Main results for change in cough intensity between baseline and day 7 are presented in Figure 3. In each trial analyzed individually as well as in the meta-analysis, where a point estimate for the treatment group difference of 0.89 points was observed, patients treated with EPs 7630 showed a significantly more pronounced reduction in the cough intensity score than those in the placebo group. No important heterogeneity of results was observed (I 2=13%). In the pooled data set in adults with AB from all trials, 331/373 (88.7%) patients treated with EPs 7630 and 129/271 (47.6%) patients in the placebo group showed a reduction of cough intensity by at least 50% compared to baseline (meta-analysis RR, EPs 7630 / placebo: 2.13; 95% CI: 1.37, 3.31) while 97/373 (26.0%) and 17/271 (6.3%) did not cough any more at day 7 (RR: 5.00; 95% CI: 3.10, 8.07).In 2 RCTs reporting adverse events, there was no difference between guaifenesin and placebo (no p values reported; very low quality evidence).

It’s important to continue treatment for 3 days after symptoms have resolved to prevent a relapse. Pelargonium safety Based on 4 RCTs from 1 systematic review ( Smith et al. 2014) in adults, young people and children with cough related to a common cold or upper respiratory tract infection. Individually, cefuroxime also showed benefit over placebo for the following outcomes: clinical improvement at follow-up, improvement at physician follow-up and night cough at follow-up, where other antibiotics did not. This was based on a trial of over 300 people, which contributed much of the weight in meta-analyses. The committee discussed this finding and had some concerns that the study design of the cefuroxime study in particular influenced this result. Liver problems including hepatitis have been reported when taking this product. However, a causal relationship has not been established. The frequency is not known. If you become unwell (yellowing eyes/skin, nausea, vomiting, dark urine, abdominal pain, unusual tiredness, loss of appetite), stop taking immediately and seek medical advice. The product can be stored for up to six months after opening. Store the product in a cool dry place. Keep the product out of the reach and sight of children. Further informationLinder JA, Sim I. Antibiotic treatment of acute bronchitis in smokers: a systematic review. J Gen Intern Med. 2002;17(3):230-234. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet. 2002;359(9318):1648-1654. Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, doubleblind, placebo-controlled trial. Phytomedicine. 2003;10(suppl 4):7-17. NSAIDs were not significantly different to placebo for overall symptom score, severity of illness, duration of illness, throat irritation or hoarseness, malaise or fatigue, chilliness, nasal irritation, pain on swallowing, eye itching, rhinorrhoea, nasal obstruction or dryness, number of nose blows, total weight of mucous, tissue count, sense of smell or adverse effects in adults with a common cold (very low to low quality evidence).